Why Treating Sarcopenia Demands a Multi-Target Strategy
A 2026 review maps the complex, multi-cellular drivers of age-related muscle loss and asks which targets matter most for future therapies.
Resumen
Sarcopenia—the progressive loss of muscle mass and strength with age—costs healthcare systems billions annually and has no approved pharmacological treatment. This comprehensive 2026 review from the Australian Physiological Society synthesizes evidence across six major biological axes: impaired protein homeostasis (notably aberrant mTORC1 overactivation), fibrosis driven by fibro-adipogenic progenitors (FAPs) and macrophage imbalance, declining muscle stem cell (MuSC) regenerative capacity, motor neuron degeneration and neuromuscular junction breakdown, senescent-like muscle fiber states, and sex hormone decline. The authors argue that focusing solely on anabolic signaling within muscle fibers is insufficient—dysfunction in motor neurons, MuSCs, and immune cells may be equally or more causally important. A personalized, multi-target treatment paradigm is proposed.
Resumen detallado
As global populations age, sarcopenia—characterized by declining muscle mass, strength, and physical function—has emerged as a critical public health challenge, costing an estimated $18 billion annually in the US alone. Despite decades of research, no pharmacological therapy is approved, and lifestyle interventions (resistance exercise, protein optimization) offer only partial protection. This review, presented at the Australian Physiological Society 2025 symposium and published in The Journal of Physiology, assembles experts across muscle biology to evaluate which cellular and molecular mechanisms should be prioritized for therapeutic development.
On proteostasis, the authors highlight a counterintuitive paradox: while anabolic signaling is blunted in aged muscle, basal mTORC1 activity is paradoxically elevated. This chronic overactivation suppresses autophagy and drives feedback inhibition of PKB/Akt, worsening atrophy. Impaired branched-chain amino acid (BCAA) catabolism and denervation-driven amino acid release from the ubiquitin-proteasome system (UPS) are proposed mechanistic contributors. Rapamycin (currently in Phase 2a trials in older adults), urolithin A (Phase 2 RCT data positive for muscle endurance), and 15-PGDH inhibition (restoring PGE2-mediated PKB/Akt signaling) are highlighted as promising but cautious avenues.
In the muscle microenvironment, fibro-adipogenic progenitors (FAPs) emerge as key architects of age-related fibrosis. Normally cleared by pro-inflammatory macrophages after injury, FAPs accumulate in aged muscle due to impaired TNFα-mediated apoptosis and a shift toward anti-inflammatory macrophage dominance, promoting TGFβ-driven ECM fibrosis. The aging ECM becomes stiffer and less mechanically responsive, impairing force transmission and mechanotransduction. Muscle stem cells (MuSCs) suffer from elevated p16, p38-MAPK, JAK-STAT, and p53 signaling, compounded by a hostile niche featuring elevated FGF2, pro-inflammatory cytokines, and ECM rigidity—all reducing their regenerative capacity.
Motor neuron health receives substantial attention. Progressive denervation, NMJ fragmentation, and motor neuron loss are identified as early and potent contributors to muscle atrophy—potentially upstream of intrinsic muscle fiber changes. Microglia-driven neuroinflammation, oxidative stress, and mitochondrial dysfunction form self-reinforcing cycles that accelerate motor neuron degeneration. Sex hormone decline (testosterone, estrogen, DHEA) adds another systemic layer, with sex-specific differences in sarcopenic trajectories underscoring the need for tailored interventions. Senescent-like muscle fibers expressing Cdkn1a and secreting SASP factors further perturb the local environment and neighboring cells.
The authors conclude that sarcopenia's multifactorial nature demands multifactorial solutions. Advances in AAV capsid engineering, antibody-targeted drug delivery, single-cell/spatial transcriptomics, and senolytics are opening new therapeutic windows. Individual variation in genetics, sex, activity levels, nutrition, and comorbidities will likely determine which mechanism is dominant in any given patient, pointing toward precision medicine frameworks for sarcopenia treatment.
Hallazgos clave
- Basal mTORC1 is paradoxically overactive in sarcopenic muscle, blocking autophagy and worsening atrophy despite reduced anabolic signaling.
- Impaired BCAA catabolism drives aberrant mTORC1 elevation and muscle wasting in both humans and mice.
- FAP accumulation and macrophage polarization imbalance promote fibrosis, stiffening the ECM and impairing muscle regeneration with age.
- Motor neuron degeneration and NMJ fragmentation may be early, causally upstream drivers of sarcopenia—not just secondary effects.
- Muscle stem cell dysfunction, senescent-like fiber states, and sex hormone decline each contribute independently to age-related muscle loss.
Metodología
This is a narrative symposium review (not a meta-analysis or original clinical trial) synthesizing evidence from rodent models, human muscle biopsy studies, single-cell omics, and early-phase clinical trials. It draws on mechanistic mouse genetic studies, human cohort data, and Phase 1–2 trial results across multiple therapeutic targets. No primary data collection was performed by the authors.
Limitaciones del estudio
As a narrative review, it does not quantitatively synthesize effect sizes or assess publication bias across studies. Most mechanistic evidence derives from rodent models with uncertain human translatability, and the relative causal weight of each proposed mechanism in human sarcopenia remains undefined. Therapeutic strategies discussed (rapamycin, 15-PGDH inhibition, senolytics) have limited long-term human safety data.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: